Pharmacia's Dipentum
Executive Summary
Overall incidence of diarrhea reported at the Sept. 16 meeting of FDA's Gastrointestinal Drugs Advisory Committee was 15.4% in the olsalazine-treated population, not 36% as reported in "The Pink Sheet" (Sept. 19, T&G-1).